ישראל - עברית - Ministry of Health

י.א.א.טכנולוגיות רפואיות בע"מ - כלל האוכלוסיה - מד לחץ דם דיגיטאלי

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - ibuprofen - תרחיף - ibuprofen 100 mg / 5 ml - ibuprofen

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - ibuprofen - תרחיף - ibuprofen 20 mg/ml - ibuprofen

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - ibuprofen - תרחיף - ibuprofen 100 mg / 5 ml - ibuprofen

ישראל - עברית - Ministry of Health

taro international ltd, israel - sildenafil as citrate - תרחיף - sildenafil as citrate 25 mg / 1 ml - sildenafil

ישראל - עברית - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

ישראל - עברית - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

ישראל - עברית - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - moroctocog alfa - אבקה וממס להכנת תמיסה להזרקה - moroctocog alfa 2000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency)

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.